Kimberly-Clark’s $48.7 Billion Kenvue Deal Draws Selloff as Cramer Backs CEO’s Bet

Investors punished the stock on liability concerns despite a quarterly earnings beat.

Overview

Kimberly-Clark announced an agreement to buy Kenvue for $48.7 billion, adding brands such as Tylenol, Band-Aid and Neutrogena.
Shares fell sharply after the takeover news, with Jim Cramer saying the stock was "clobbered."
Before the deal reaction, Kimberly-Clark reported earnings of $1.82 per share versus $1.76 expected, and it highlights a roughly 5% yield and a strong balance sheet.
Cramer endorsed the acquisition and praised CEO Mike Hsu, arguing the purchase could make Kimberly-Clark a much larger company at a lower price and broaden its geographic strengths.
Commentary acknowledged legacy legal exposure tied to Kenvue’s products, with Cramer noting investors’ concern over litigation and suggesting penalties may be less severe in Europe.